PTEN Knockout Prostate Cancer as a Model for Experimental Immunotherapy

Journal of Urology

Volumn 181, Issue 1, 2009, Pages 354-362

  Haga, Kazunori ^a   Tomioka, Atsushi ^a,e   Liao, Chun Peng ^c   Kimura, Takahiro ^a,f   Matsumoto, Hiroshi ^a   Ohno, Izumi ^a   Hermann, Kip ^a   Logg, Christopher R ^a   Jiao, Jing ^b   Tanaka, Motoyoshi ^g   Hirao, Yoshihiko ^e   Wu, Hong ^a,b   Kruse, Carol A ^d   Roy Burman, Pradip ^c   Kasahara, Noriyuki ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d SIDNEY KIMMEL CANCER CENTER   (United States)

^e NARA MEDICAL UNIVERSITY   (Japan)

^f JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g KINKI UNIVERSITY   (Japan)

Author keywords

adoptive; cancer vaccines; immunotherapy; mouse; PLIP protein; prostate; prostatic neoplasms

Indexed keywords

GAMMA INTERFERON; LUCIFERASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; TUMOR CELL VACCINE;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLOGICAL MONITORING; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER MODEL; CANCER PREVENTION; CANCER SIZE; CELL PROLIFERATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; EFFECTOR CELL; EXPERIMENTAL MODEL; KNOCKOUT MOUSE; MALE; MIXED LYMPHOCYTE REACTION; NONHUMAN; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; SPLEEN CELL; TARGET CELL DESTRUCTION; TREATMENT OUTCOME;

ADENOCARCINOMA; ANIMALS; CANCER VACCINES; IMMUNIZATION; MALE; MICE; MICE, KNOCKOUT; PROSTATIC NEOPLASMS; PTEN PHOSPHOHYDROLASE;

EID: 57149100358     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2008.08.124     Document Type: Article

References (27)

1. Jemal A., Murray T., Ward E., Samuels A., Tiwari R.C., Ghafoor A., et al. Cancer statistics, 2005. CA Cancer J Clin 55 (2005) 10
2. McNeel D.G. Prostate cancer immunotherapy. Curr Opin Urol 17 (2007) 175
3. Kruse C.A., and Rubinstein D. Cytotoxic T lymphocytes reactive to patient major histocompatibility proteins for therapy of recurrent primary brain tumors. In: Liau L.M., Becker D.P., Cloughsey T.F., and Bigner D.D. (Eds). Brain Tumor Immunotherapy (2001), Humana Press, New York 149-170
4. Buhler P., Wolf P., Gierschner D., Schaber I., Katzenwadel A., Schultze-Seemann W., et al. A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells. Cancer Immunol Immunother 57 (2008) 43
5. Gade T.P., Hassen W., Santos E., Gunset G., Saudemont A., Gong M.C., et al. Targeted elimination of prostate cancer by genetically directed human T lymphocytes. Cancer Res 65 (2005) 9080
6. Pinthus J.H., Waks T., Kaufman-Francis K., Schindler D.G., Harmelin A., Kanety H., et al. Immuno-gene therapy of established prostate tumors using chimeric receptor-redirected human lymphocytes. Cancer Res 63 (2003) 2470
7. Young J.G., Green N.K., Mautner V., Searle P.F., Young L.S., and James N.D. Combining gene and immunotherapy for prostate cancer. Prostate Cancer Prostatic Dis (2007)
8. Zhang Q., Yang X., Pins M., Javonovic B., Kuzel T., Kim S.J., et al. Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive CD8+ T cells: eradication of autologous mouse prostate cancer. Cancer Res 65 (2005) 1761
9. Anderson M.J., Shafer-Weaver K., Greenberg N.M., and Hurwitz A.A. Tolerization of tumor-specific T cells despite efficient initial priming in a primary murine model of prostate cancer. J Immunol 178 (2007) 1268
10. Roy-Burman P., Wu H., Powell W.C., Hagenkord J., and Cohen M.B. Genetically defined mouse models that mimic natural aspects of human prostate cancer development. Endocr Relat Cancer 11 (2004) 225
11. Tennant T.R., Kim H., Sokoloff M., and Rinker-Schaeffer C.W. The Dunning model. Prostate 43 (2000) 295
12. Goebel H.W., Rausch U., Steinhoff M., Seitz J., Bacher M., Papotti M., et al. Arguments against the prostatic origin of the R-3327 Dunning H tumor. Virchows Arch B Cell Pathol Incl Mol Pathol 62 (1992) 9
13. Stambolic V., Suzuki A., de la Pompa J.L., Brothers G.M., Mirtsos C., Sasaki T., et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 95 (1998) 29
14. Cairns P., Okami K., Halachmi S., Halachmi N., Esteller M., Herman J.G., et al. Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res 57 (1997) 4997
15. Mulholland D.J., Dedhar S., Wu H., and Nelson C.C. PTEN and GSK3beta: key regulators of progression to androgen-independent prostate cancer. Oncogene 25 (2006) 329
16. Wang S., Gao J., Lei Q., Rozengurt N., Pritchard C., Jiao J., et al. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 4 (2003) 209
17. Jiao J., Wang S., Qiao R., Vivanco I., Watson P.A., Sawyers C.L., et al. Murine cell lines derived from Pten null prostate cancer show the critical role of PTEN in hormone refractory prostate cancer development. Cancer Res 67 (2007) 6083
18. Bhaumik S., and Gambhir S.S. Optical imaging of Renilla luciferase reporter gene expression in living mice. Proc Natl Acad Sci U S A 99 (2002) 377
19. Tomayko M.M., and Reynolds C.P. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol 24 (1989) 148
20. Hiraoka K., Kimura T., Logg C.R., and Kasahara N. Tumor-selective gene expression in a hepatic metastasis model after locoregional delivery of a replication-competent retrovirus vector. Clin Cancer Res 12 (2006) 7108
21. Brakenhielm E., Burton J.B., Johnson M., Chavarria N., Morizono K., Chen I., et al. Modulating metastasis by a lymphangiogenic switch in prostate cancer. Int J Cancer 121 (2007) 2153
22. Liao C.P., Zhong C., Saribekyan G., Bading J., Park R., Conti P.S., et al. Mouse models of prostate adenocarcinoma with the capacity to monitor spontaneous carcinogenesis by bioluminescence or fluorescence. Cancer Res 67 (2007) 7525
23. North R.J. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J Exp Med 155 (1982) 1063
24. Gomez G.G., Hutchison R.B., and Kruse C.A. Chemo-immunotherapy and chemo-adoptive immunotherapy of cancer. Cancer Treat Rev 27 (2001) 375
25. Kruse C.A., Mitchell D.H., Kleinschmidt-DeMasters B.K., Bellgrau D., Eule J.M., Parra J.R., et al. Systemic chemotherapy combined with local adoptive immunotherapy cures rats bearing 9L gliosarcoma. J Neurooncol 15 (1993) 97
26. Dudley M.E., Wunderlich J.R., Yang J.C., Sherry R.M., Topalian S.L., Restifo N.P., et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 23 (2005) 2346
27. Rosenberg S.A., Yang J.C., Robbins P.F., Wunderlich J.R., Hwu P., Sherry R.M., et al. Cell transfer therapy for cancer: lessons from sequential treatments of a patient with metastatic melanoma. J Immunother 26 (2003) 385